When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...
Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for ...
Effect of fusobacterium nucleatum on NF-κB/HIF-1α/CCL20 pathway and M2 macrophages infiltration in esophageal squamous cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Leronlimab increases PD-L1 expression on circulating tumor cells, potentially converting "cold" tumors to "hot" ones, enhancing immune response in metastatic triple-negative breast cancer. In a study, ...
Impact of body mass index (BMI) on survival outcomes in patients with cancer treated with immune checkpoint inhibitors (ICPI): A systematic review and meta analysis. This is an ASCO Meeting Abstract ...
US FDA approves Agilent’s PD-L1 IHC 28-8 pharmDx assay in ESCC, gastric, GEJ and esophageal adenocarcinoma: Santa Clara, California Thursday, July 16, 2026, 11:00 Hrs [IST] Agil ...
MedPage Today on MSN
Biomarkers for esophageal cancer continue to evolve
Recently validated markers have helped improve treatment but more are needed ...
Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status. Keytruda (pembrolizumab) plus chemotherapy improved ...
The first clinical case presents a 58-year-old female never-smoker with persistent cough, mild dyspnea, and new right-sided ...
Morning Overview on MSN
A breast-cancer drug slowed tumors in a trial of hard-to-treat patients
Patients with triple-negative breast cancer who cannot receive immunotherapy now have a new first-line treatment option after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results